177 related articles for article (PubMed ID: 37391640)
1. The m6A modulator-mediated cytarabine sensitivity and immune cell infiltration signature in acute myeloid leukemia.
Yang J; Li L; Cheng J; Lu J; Zhang S; Wang S; Zhao L; Zhou L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11457-11469. PubMed ID: 37391640
[TBL] [Abstract][Full Text] [Related]
2. DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia.
Sun H; Ren Y; Zhou X; Chen Q; Liu Y; Zhu C; Ruan Y; Ruan H; Tong H; Ying S; Lin P
Technol Cancer Res Treat; 2023; 22():15330338231207765. PubMed ID: 37872685
[No Abstract] [Full Text] [Related]
3. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
4. m6A genotypes and prognostic signature for assessing the prognosis of patients with acute myeloid leukemia.
Fu C; Kou R; Meng J; Jiang D; Zhong R; Dong M
BMC Med Genomics; 2023 Aug; 16(1):191. PubMed ID: 37596597
[TBL] [Abstract][Full Text] [Related]
5. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis.
Zhang H; Liu L; Chen L; Liu H; Ren S; Tao Y
Mol Oncol; 2021 Apr; 15(4):1203-1216. PubMed ID: 33638615
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
te Boekhorst PA; Löwenberg B; Sonneveld P
Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
[TBL] [Abstract][Full Text] [Related]
8. Analysis of m6A-related signatures associated with the tumor immune microenvironment and predict survival in acute myeloid leukemia.
Yuan S; Cong Z; Ji J; Zhu L; Jiang Q; Zhou Y; Shen Q; Damiani D; Xu X; Li B
Ann Transl Med; 2022 Aug; 10(16):902. PubMed ID: 36111007
[TBL] [Abstract][Full Text] [Related]
9. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
10. Construction of an acute myeloid leukemia prognostic model based on m6A-related efferocytosis-related genes.
Wang Y; Bin T; Tang J; Xu XJ; Lin C; Lu B; Sun TT
Front Immunol; 2023; 14():1268090. PubMed ID: 38077322
[TBL] [Abstract][Full Text] [Related]
11. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
12. Tumor-suppressive MEG3 induces microRNA-493-5p expression to reduce arabinocytosine chemoresistance of acute myeloid leukemia cells by downregulating the METTL3/MYC axis.
Wang A; Chen Y; Shi L; Li M; Li L; Wang S; Wang C
J Transl Med; 2022 Jun; 20(1):288. PubMed ID: 35761379
[TBL] [Abstract][Full Text] [Related]
13. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
14. Prognosis and Characterization of Immune Microenvironment in Acute Myeloid Leukemia Through Identification of an Autophagy-Related Signature.
Fu D; Zhang B; Wu S; Zhang Y; Xie J; Ning W; Jiang H
Front Immunol; 2021; 12():695865. PubMed ID: 34135913
[TBL] [Abstract][Full Text] [Related]
15. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.
Zhang F; Sun J; Tang X; Liang Y; Jiao Q; Yu B; Dai Z; Yuan X; Li J; Yan J; Zhang Z; Fan S; Wang M; Hu H; Zhang C; Lv XB
Cell Death Dis; 2022 Jul; 13(7):590. PubMed ID: 35803902
[TBL] [Abstract][Full Text] [Related]
16. E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
Liu Y; Chen P; Chen G; Chen X
Ann Hematol; 2023 Dec; 102(12):3345-3355. PubMed ID: 37665348
[TBL] [Abstract][Full Text] [Related]
17. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
[TBL] [Abstract][Full Text] [Related]
19. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
20. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
